Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Immuno-Oncology Development.
TLR9 Molecular Basis & Key Mutations
TLR9 (Toll-like receptor 9, CD289) is an endosomal pattern recognition receptor (PRR) that senses unmethylated CpG DNA. Its intracellular TIR domain (residues 869–1032) mediates downstream NF-κB and IRF signaling. Clinically relevant single nucleotide polymorphisms (SNPs) include:
- rs5743842 (UniProt VAR_024668): associated with altered response to infectious diseases.
- rs5743843 (UniProt VAR_052364): linked to autoimmune susceptibility.
- rs5743845 (UniProt VAR_034555): impacts TLR9 function in plasmacytoid dendritic cells.
These mutations underscore the importance of sequence-verified reagents for allele-specific assay development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TLR9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TLR9 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TLR9 Products |
| Gene Delivery | TLR9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Suitable for NF-κB reporter assays. Endotoxin controlled. |
View TLR9 Products |
| Benchmark Ab | Anti-TLR9 (Functional Grade / Research Grade Recombinant Clone) Recombinant positive control for blocking/activation, detection, and flow cytometry. |
View TLR9 Products |
| Validator | TLR9 siRNA Set For knockdown verification in pDC or engineered cell lines. |
View TLR9 Products |
| Related Target: TLR7 | TLR7 Endosomal TLR synergy; critical for off-target profiling in autoimmune indications and dual-agonism/antagonism. |
View TLR7 Products |
| Related Target: TLR8 | TLR8 Myeloid cell nucleic acid sensor; essential for TLR7/8/9 cross-reactivity profiling and off-target liability assessment. |
View TLR8 Products |
| Related Target: BDCA2 | BDCA2 (CD303) Plasmacytoid dendritic cell marker; alternative pDC modulation strategy for SLE. |
View BDCA2 Products |
| Related Target: STING1 | STING1 Synergistic innate immune pathway activation for oncology; often evaluated alongside TLR9 agonists. |
View STING1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Endosomal signaling context (TLR9 requires proteolytic processing and acidification) | TLR9 Lentivirus for Stable Cell Line construction; cell-based assays preserve endosomal trafficking and conformation. |
| TLR7/8/9 subfamily selectivity and off-target inflammation | Human TLR7, TLR8, and TLR9 ECD-Fc ortholog proteins (>95% purity) available for parallel SPR/BLI binding panels and dual-reporter counter-screens. |
| Cross-species CpG motif recognition (Human vs. Mouse vs. Cyno) | Human, Mouse, and Cynomolgus TLR9 ECD-Fc proteins (>95% purity, Sequence Verified) enable ortholog binding comparison and preclinical translation. |
| Lack of specific controls in ODN agonist screens | TLR9 siRNA Set for knockdown specificity confirmation; recombinant Benchmark Ab for receptor occupancy studies; Clinical Benchmark CpG ODNs included. |
| False positives in reporter assays | Validated siRNA included for specificity checks; TLR9-KD cell lines available. |
Live TLR9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The TLR9 therapeutic landscape is bifurcated between antagonist strategies for systemic lupus erythematosus (SLE) and psoriasis—where blocking self-CpG DNA sensing quells plasmacytoid dendritic cell (pDC) activation—and agonist strategies for immuno-oncology, where CpG oligonucleotides stimulate anti-tumor immunity. As first-generation CpG ODNs face delivery and systemic toxicity limitations, the next wave of R&D is targeting antibody-based TLR9 modulators, nanoparticle-conjugated agonists (e.g., spherical nucleic acids), and tissue-specific decoy receptors to improve safety margins. Major players include Dynavax (SD-101, Heplisav-B adjuvant), Checkmate Pharmaceuticals (vidutolimod), Idera Pharmaceuticals (IMO-2055, antagonists for SLE), and Exicure (SNA conjugates). Combination with immune checkpoint inhibitors (e.g., Keytruda) is a key trend in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CpG ODN Agonist | Dynavax, Checkmate/Regeneron, Idera, Exicure | Melanoma, Lymphoma, HNSCC, Infectious Disease Adjuvants | pDC Activation Assay & TLR9 Stable Cell Line Reporter (Need high-purity TLR9 ECD for binding competition; lentivirus for endosomal signaling preservation) |
| CpG Antagonist / Inhibitor | Idera (IMO-2055), Mologen | SLE, Cutaneous Lupus | Self-DNA Binding Blockade (Need TLR9 WT vs Mutant proteins for selectivity) |
| Anti-TLR9 mAb | Emerging Biotechs | Autoimmune | Epitope Binning & Internalization (Need full-length Lentivirus cell lines) |
| Nanoparticle / SNA Conjugate | Exicure, academic consortia | Solid Tumors (intratumoral) | Internalization & Endosomal Escape Assay (Need high-purity TLR9 ECD-Fc for binding + cell lines for trafficking) |
| Combination (TLR9 + Anti-PD-1) | MSD (Keytruda combos), Regeneron | Anti-PD-1 refractory solid tumors | Cytokine Release & Selectivity Panel (Need TLR7/8/9 ortholog proteins and siRNA validators) |
| BDCA2 Targeting (pDC depletion) | Biogen (Litifilimab) | SLE | Pathway Cross-talk Assay (Need TLR9+BDCA2 co-expression systems) |
TarMart Reagent Summary
| Product Category | Key Features |
|---|---|
| TLR9 ECD-Fc Protein (Human/Mouse/Cyno) | >95% purity, <1EU/ug endotoxin, sequence verified, HEK293 expressed (native glycosylation). Available as wild-type or mutant (rs5743842/43/45). |
| TLR9 Lentivirus (Full-length ORF) | Suitable for stable cell line generation; preserves endosomal proteolytic processing and NF-κB reporter readout. |
| Anti-TLR9 Benchmark Antibody | Functional grade recombinant clone; validated for blocking, detection, and flow cytometry. |
| TLR9 siRNA Set | For specific knockdown verification in pDC or engineered cell lines. |